Real-world biomarker testing patterns in metastatic castration-resistant prostate cancer patients

被引：0
|
作者：
Blanc, Simon
Adeboyeje, Gboyega
Lee, Liam
Gart, Mike
Saunders, William
Wang, Brandon
Dave, Poras
English, Sandy
Varughese, Prateesh
Sillah, Arthur
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-920
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
920
引用
收藏
页数：2
相关论文
共 50 条
  • [41] REAL-WORLD DATA ON METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE IN REGIONAL ONCOLOGY SERVICE
    Lie, Gabrielle
    Wong, Zee Wan
    Saqib, Ayesha
    Tamjid, Babak
    Torres, Javier
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 51 - 51
  • [42] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    M. Koninckx
    J. L. Marco
    I. Pérez
    M. T. Faus
    V. Alcolea
    F. Gómez
    Clinical and Translational Oncology, 2019, 21 : 314 - 323
  • [43] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [44] Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.
    Antonarakis, Emmanuel S.
    Zhang, Nicole
    Saha, Jayati
    Nevalaita, Liina
    Shell, Scott A.
    Garratt, Chris
    Ikonen, Tarja
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
    Liu, Min
    Yan, Jiaqing
    Le, Kaidi
    Li, Ying
    Xing, Nianzeng
    Li, Guohui
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [46] A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China
    He, Dalin
    Sun, Zhongquan
    Guo, Jianming
    Zhang, Zhigen
    Shan, Yuxi
    Ma, Lulin
    Li, Hanzhong
    Jin, Jie
    Huang, Yiran
    Xiao, Jiaquan
    Wei, Qiang
    Ye, Dingwei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (03) : 144 - 150
  • [47] COMPARISON OF THE CARDIOTOXICITY OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING REAL-WORLD DATA
    Hu, Jason
    Aprikian, Armen
    Vanhuyse, Marie
    Dragomir, Alice
    JOURNAL OF UROLOGY, 2021, 206 : E418 - E419
  • [48] How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Seyednasrollah, Fatemeh
    Mahmoudian, Mehrad
    Rautakorpi, Liisa
    Hirvonen, Outi
    Laitinen, Tarja
    Jyrkkio, Sirkku
    Elo, Laura L.
    EUROPEAN UROLOGY, 2017, 71 (05) : 838 - 840
  • [49] REAL-WORLD TREATMENT AND CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH OLAPARIB IN THE UNITED STATES
    Daniel, J. George
    Furaha, Kariburyo-Yay
    Himani, Aggarwal
    Jon, Tepsick
    Rebekah, Yu
    Weiyan, Li
    Chinelo, Orji
    Sameer, R. Ghate
    Neeraj, Agarwal
    Michael, T. Schweizer
    Elena, Castro
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [50] Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population.
    Freedland, Stephen J.
    Davis, Matthew
    Epstein, Andrew J.
    Arondekar, Bhakti
    Ivanova, Jasmina I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 406 - 406
12345